Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 19/20 | 0.35 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.30 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.30 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.30 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600394 | 0.89 | SLC5A2 (0.45) | SLC5A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL15888756 | 0.84 | SLC5A2 (0.36) | SLC5A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL222748 | 0.84 | SLC5A2 (0.36) | SLC5A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL15888755 | 0.80 | SSTR1 (0.36) | SLC5A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL2600391 | 0.80 | SLC5A2 (0.53) | SLC5A2 | |
| SCHEMBL2600390 | 0.79 | SLC5A2 (0.34) | SLC5A2 | |
| SCHEMBL12993566 | 0.77 | SLC5A2 (0.33) | SLC5A2 | |
| SCHEMBL2600477 | 0.77 | SLC5A2 (0.41) | SLC5A2 | |
| SCHEMBL2600479 | 0.77 | SLC5A2 (0.45) | SLC5A2 | |
| SCHEMBL14235767 | 0.77 | SLC5A2 (0.45) | SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541380-B2 | C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same | GREEN CROSS CORPORATION (KR) | 2013-09-24 | — | — | US | disclosed |
| US-20120101051-A1 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-04-26 | — | — | US | disclosed |
| WO-2010147430-A2 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101051-A1 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SSTR1 2149/4885SSTR2 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.